Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin at steady-state levels: a randomized, open-label, two-way, crossover, Phase I study

Clinical Therapeutics

Volumn 30, Issue 9, 2008, Pages 1639-1650

  Solans, Anna ^a   Izquierdo, Iñaki ^a   Donado, Esther ^a   Antonijoan, Rosa ^b   Peña, Juana ^a   Nadal, Teresa ^a   Carbó, Marcel lí ^a   Merlos, Manuel ^a   Barbanoj, Manel ^b  

^a J Uriach y Compania   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

azithromycin; drug drug interactions; rupatadine

Indexed keywords

3 HYDROXYDESLORATADINE; AZITHROMYCIN; DESLORATADINE; DRUG METABOLITE; RUPATADINE; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; ADULT; ALLERGIC RHINITIS; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CHRONIC URTICARIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MULTIPLE DRUG DOSE; NORMAL HUMAN; OPEN STUDY; PARAMETER; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; SOMNOLENCE; STEADY STATE; TANDEM MASS SPECTROMETRY;

ADMINISTRATION, ORAL; ADULT; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; AZITHROMYCIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CONFIDENCE INTERVALS; CROSS-OVER STUDIES; CYPROHEPTADINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; HISTAMINE H1 ANTAGONISTS; HUMANS; LORATADINE; MALE; SAFETY; THERAPEUTIC EQUIVALENCY;

EID: 53049087887     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2008.09.002     Document Type: Article

References (26)

1. Merlos M., Giral M., Balsa D., et al. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF). J Pharmacol Exp Ther 280 (1997) 114-121
2. Keam S.J., and Plosker G.L. Rupatadine: A review of its use in the management of allergic disorders. Drugs 67 (2007) 457-474
3. Pérez I., de la Cruz G., Villa M., and Izquierdo I. Rupatadine in allergic rhinitis: Pooled analysis of efficacy data. Allergy 57 Suppl 73 (2002) 245
4. Martínez-Cócera C., De Molina M., Martí-Guadaño E., et al., Spanish Rupatadine Rhinitis Study Group. Rupatadine 10 mg and cetirizine 10 mg in seasonal allergic rhinitis: A randomised, double-blind parallel study. J Investig Allergol Clin Immunol 15 (2005) 22-29
5. Saint-Martin F., Dumur J.P., Pérez I., Izquierdo I., and French Rupatadine-Rhinitis Study Group. A randomized, double-blind, parallel-group study, comparing the efficacy and safety of rupatadine (20 and 10 mg), a new PAF and H1 receptor-specific histamine antagonist, to loratadine 10 mg in the treatment of seasonal allergic rhinitis. J Investig Allergol Clin Immunol 14 (2004) 34-40
6. Guadańo E.M., Serra-Batlles J., Meseguer J., et al., Rupatadine Study Group. Rupatadine 10 mg and ebastine 10 mg in seasonal allergic rhinitis: A comparison study. Allergy 59 (2004) 766-771
7. Barbanoj M.J., García-Gea C., Morte A., et al. Central and peripheral evaluation of rupatadine, a new antihistamine/platelet-activating factor antagonist, at different doses in healthy volunteers. Neuropsychobiology 50 (2004) 311-321
8. Shakeri-Nejad K., and Stahlmann R. Drug interactions during therapy with three major groups of antimicrobial agents. Expert Opin Pharmacother 7 (2006) 639-651
9. Bjornsson T.D., Callaghan J.T., Einolf H.J., et al., Pharmaceutical Research and Manufacturers of America (PhRMA) Drug Metabolism/Clinical Pharmacology Technical Working Group and FDA Center for Drug Evaluation and Research (CDER). The conduct of in vitro and in vivo drug-drug interaction studies: A Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 31 (2003) 815-832
10. Westphal J.F. Macrolide-induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: An update focused on clarithromycin, azithromycin and dirithromycin. Br J Clin Pharmacol 50 (2000) 285-295
11. Zhou S., Yung Chan S., Cher Goh B., et al. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet 44 (2005) 279-304
12. Gupta S., Banfield C., Kantesaria B., et al. Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin: A randomized, placebocontrolled, parallel-group study. Clin Ther 23 (2001) 451-466
13. Schwarz U.I., Gramatté T., Krappweis J., et al. P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans. Int J Clin Pharmacol Ther. 38 (2000) 161-167
14. Christie B. Doctors revise declaration of Helsinki. BMJ 321 (2000) 913
15. European Agency for the Evaluation of Medicinal Products, International Conference on Harmonisation-World Health Organization. Guideline for Good Clinical Practice [EMEA Web site]. ICH Topic E6. Step 5. Note for guidance on Good Clinical Practice (CPMP/ICH/135/95). Geneva, Switzerland: WHO; 2002. http://www.emea.eu.int. Accessed April 11, 2007.
16. Guidance for Industry. Bioanalytical Method Validation US Dept of Health and Human Services. Food and Drug Administration, Center for Drug Evaluation and Research (CDER) Center for Veterinary Medicine (CVM), May 2001.
17. Shah V.P., Midha K.K., Findlay J.W., et al. Bioanalytical method validation-A revisit with a decade of progress. Pharm Res 17 (2000) 1551-1557
18. Guidance for Industry. Statistical approaches to establishing bioequivalence. US Dept of Health and Human Services. Food and Drug Administration, Center for Drug Evaluation and Research (CDER), January 2001.
19. Zithromax (azithromycin) clinical pharmacology. Pharmacokinetics [Rxlist Web site]. http://www.rxlist.com/cgi/generic/azith_cp.htm. Accessed May 11, 2005.
20. von Rosensteil N.A., and Adam D. Macrolide antibacterials. Drug interactions of clinical significance. Drug Saf 13 (1995) 105-122
21. Sugie M., Asakura E., Zhao Y.L., et al. Possible involvement of the drug transporters P glycoprotein and multidrug resistance-associated protein Mrp2 in disposition of azithromycin. Antimicrob Agents Chemother 48 (2004) 809-814
22. Muirhead G.J., Faulkner S., Harness J.A., and Taubel J. The effects of steady-state erythromycin and azithromycin on the pharmacokinetics of sildenafil in healthy volunteers. Br J Clin Pharmacol. 53 Suppl 1 (2002) 37S-43S
23. Purkins L., Wood N., Ghahramani P., et al. No clinically significant effect of erythromycin or azithromycin on the pharmacokinetics of voriconazole in healthy male volunteers. Br J Clin Pharmacol. 56 Suppl 1 (2003) 30-36
24. Clarinex (desloratadine). Summary product characteristics [Web site]. http://www.spfiles.com/piclarinex.pdf. Accessed April 7, 2008.
25. Frick G.S., Blum R.A., Kovacs S.J., et al. Prevalence of the slow metabolizer (SM) phenotype and single dose pharmacokinetics (PK) of desloratadine (DCL) in a population of healthy adults. Clin Pharmacol Ther 75 (2004) 9
26. Prenner B., Kim K., Gupta S., et al. Adult and paediatric poor metabolisers of desloratadine: An assessment of pharmacokinetics and safety. Expert Opin Drug Saf 5 (2006) 211-223